Deferiprone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Deferiprone
Deferiprone.svg
Clinical data
Trade names Ferriprox
AHFS/Drugs.com International Drug Names
License data
Pregnancy
category
  • US: D (Evidence of risk)
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Metabolism Glucuronidation
Biological half-life 2 to 3 hours
Excretion Renal (75 to 90% in 24 hours)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard 100.157.470
Chemical and physical data
Formula C7H9NO2
Molar mass 139.152 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Deferiprone (tradenames include Ferriprox) is a drug that chelates iron and is used to treat iron overload in thalassaemia major.[1] It was first approved for use in treating thalassaemia major in 1994[2] and had been licensed for use in Europe and Asia for many years while awaiting approval in Canada and the United States.[1][3] On October 14, 2011, it was approved for use in the US under the FDA’s accelerated approval program.[4]

Controversy[edit]

Deferiprone was at the center of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and the pharmaceutical company Apotex, that started in 1996 and delayed approval of the drug in North America.[5] Dr. Olivieri's data suggested deferiprone leads to progressive hepatic fibrosis.[6][7]

See also[edit]

References[edit]

  1. ^ a b Savulescu J (2004). "Thalassaemia major: the murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373Freely accessible. PMID 14962851.  Full Text.
  2. ^ Staff, Cipla. Cipla's History
  3. ^ http://www.docguide.com/dg.nsf/PrintPrint/F8BC7049D350C2AD852568A2006FEAAC
  4. ^ FDA NEWS RELEASE: FDA Approves Ferripox (deferiprone) to Treat Patients with Excess Iron in the Body, Oct. 14, 2011 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm
  5. ^ Viens A, Savulescu J (2004). "Introduction to The Olivieri symposium.". J Med Ethics. 30 (1): 1–7. doi:10.1136/jme.2003.006577. PMC 1757126Freely accessible. PMID 14872065. 
  6. ^ Brittenham G, Nathan D, Olivieri N, Porter J, Pippard M, Vichinsky E, Weatherall D (2003). "Deferiprone and hepatic fibrosis". Blood. 101 (12): 5089–90; author reply 5090–1. doi:10.1182/blood-2002-10-3173. PMID 12788794.  Full Text.
  7. ^ Wanless I, Sweeney G, Dhillon A, Guido M, Piga A, Galanello R, Gamberini M, Schwartz E, Cohen A (2002). "Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia". Blood. 100 (5): 1566–9. doi:10.1182/blood-2002-01-0306. PMID 12176871.  Full Text.